Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7340225 | 0.82 | PLAU (0.54) | GLO1PTPN1PLAU | |
| Trifluoroacetic Acid SCHEMBL7456126 | 0.81 | TRPV1 (0.40) | HDAC1TRPV1KDM4EPLAU | |
| Trifluoroacetic Acid SCHEMBL7337767 | 0.79 | PLAU (0.43) | HDAC1TRPV1PTPN1ALDH1A1PLAU | |
| Trifluoroacetic Acid SCHEMBL7340772 | 0.79 | KDM4E (0.44) | TRPV1KDM4EALDH1A1HPGDPLAU | |
| Trifluoroacetic Acid SCHEMBL7343434 | 0.76 | CYP1A2 (0.43) | TRPV1KDM4EALDH1A1PLAU | |
| SCHEMBL7335335 | 0.73 | TRPV1 (0.43) | TRPV1KDM4EPLAU | |
| SCHEMBL7335604 | 0.73 | KDM4E (0.58) | TRPV1KDM4EALDH1A1HPGDPLAU | |
| SCHEMBL28028822 | 0.72 | GLO1 (0.62) | GLO1ACLYKDM4EALDH1A1HPGD | |
| SCHEMBL7344916 | 0.70 | MAPT (0.42) | TRPV1KDM4EALDH1A1PLAU | |
| Trifluoroacetic Acid SCHEMBL7335945 | 0.70 | PTGS2 (0.50) | KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | claimed |
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | GLO1 992/4885ACLY 2562/4885HDAC1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.